Table 2:

Clinicopathologic characteristics

	Vandetanib	Placebo	p value
Number	6	4	n/a
Median age, years, (range)	57 (50-71)	65 (45-72)	0.33
ER+/PR+/HER2−	6 (100%)	4 (100%)	1.0
Ductal Histology	5 (83%)	4 (100%)	1.0
Race — Non-Hispanic White	6 (100%)	4 (100%)	1.0
Stage
Stage I	1 (17%)	2 (50%)	0.50
Stage II	5 (83%)	2 (50%)
Adverse event (any)	5 (83%)	2 (50%)	0.50
Grade 1	4 (80%)	2 (100%)	1.0
Grade 2	1 (20%)	0 (0%)	1.0
Operation
Mastectomy	2 (33%)	1 (25%)	1.0
Lumpectomy	4 (67%)	3 (75%)
Complication (any)	1 (17%)	0 (0%)	1.0
Grade 3	1 (100%)	n/a
Chemotherapy	1 (17%)	0 (0%)	1.0
Radiation	4 (67%)	3 (75%)	1.0